161 related articles for article (PubMed ID: 17214355)
1. Survival markers related to bone metastases in prostate cancer.
Salminen EK; Kallioinen MJ; Ala-Houhala MA; Vihinen PP; Tiitinen SL; Varpula M; Vahlberg TJ
Anticancer Res; 2006; 26(6C):4879-84. PubMed ID: 17214355
[TBL] [Abstract][Full Text] [Related]
2. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer.
Salminen E; Ala-Houhala M; Korpela J; Varpula M; Tiitinen SL; Halleen JM; Väänänen HK
Acta Oncol; 2005; 44(7):742-7. PubMed ID: 16227166
[TBL] [Abstract][Full Text] [Related]
3. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
4. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
[TBL] [Abstract][Full Text] [Related]
6. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
7. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
[TBL] [Abstract][Full Text] [Related]
8. Tartrate-resistant acid phosphatase 5b as serum marker of bone metabolism in cancer patients.
Mose S; Menzel C; Kurth AA; Obert K; Breidert I; Borowsky K; Böttcher HD
Anticancer Res; 2003; 23(3C):2783-8. PubMed ID: 12926113
[TBL] [Abstract][Full Text] [Related]
9. High Uric Acid (UA) Negatively Affects Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b) Immunoassay.
Wu ZQ; Zhang Y; Xie E; Song WJ; Yang RX; Yan CJ; Zhang BF; Xu HG
PLoS One; 2016; 11(1):e0147554. PubMed ID: 26800211
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of tartrate-resistant acid phosphatase (TRACP) 5b as bone resorption marker in irradiated bone metastases.
Mose S; Menzel C; Kurth AA; Obert K; Ramm U; Eberlein K; Boettcher HD; Pichlmeier U
Anticancer Res; 2005; 25(6C):4639-45. PubMed ID: 16334155
[TBL] [Abstract][Full Text] [Related]
12. Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer.
Wada N; Ishii S; Ikeda T; Enomoto K; Kitajima M
Anticancer Res; 1999; 19(5C):4515-21. PubMed ID: 10650803
[TBL] [Abstract][Full Text] [Related]
13. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption.
Halleen JM
Anticancer Res; 2003; 23(2A):1027-9. PubMed ID: 12820342
[TBL] [Abstract][Full Text] [Related]
14. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
Wakabayashi H; Nakajima K; Mizokami A; Namiki M; Inaki A; Taki J; Kinuya S
Ann Nucl Med; 2013 Nov; 27(9):802-7. PubMed ID: 23828554
[TBL] [Abstract][Full Text] [Related]
15. Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis.
Chao TY; Wu YY; Janckila AJ
Clin Chim Acta; 2010 Nov; 411(21-22):1553-64. PubMed ID: 20599857
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic significance of tartrate-resistant acid phosphatase type 5b in newly diagnosed prostate cancer with bone metastasis: A real-world multi-institutional study.
Yamamichi G; Kato T; Yumiba S; Tomiyama E; Koh Y; Nakano K; Matsushita M; Hayashi Y; Ishizuya Y; Watabe T; Hatano K; Kawashima A; Ujike T; Ono Y; Takada T; Takada S; Imamura R; Nonomura N; Uemura M
Int J Urol; 2023 Jan; 30(1):70-76. PubMed ID: 36305578
[TBL] [Abstract][Full Text] [Related]
17. Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma.
Desoize B; Amico S; Larbre H; Coninx P; Jardillier JC
Clin Biochem; 1991 Oct; 24(5):443-6. PubMed ID: 1760884
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.
Jung K; Lein M; Ringsdorf M; Roigas J; Schnorr D; Loening SA; Staack A
J Urol; 2006 Oct; 176(4 Pt 1):1326-31. PubMed ID: 16952623
[TBL] [Abstract][Full Text] [Related]
19. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
[TBL] [Abstract][Full Text] [Related]
20. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
